This study is designed to determine the efficacy
of the LifeOne on terminal cancer patients. Efficacy
is to be determined by remission only. CEA, PSÁ,
CA125 and other specific antigen tests will be
used when possible to help verify remission. However,
AMAS testing in the normal range will be the only
accepted final test to determine remission. Other
testing to be completed will be CBC, Comprehensive
Metabolic and Lymphocyte Subset Panel (lymphocyte
immunophenotype enumeration) including Natural
Killer Cell Functional Assay. These tests will
determine the effect of LifeOne on the immune
system as well as verify the AMAS results.
Candidates for the research must have undergone
biopsy to verify malignancy. CBC's with all immune
markers in the normal range will be required to
determine validity of the AMAS test.
Prior use of chemotherapy or radiation will not
disqualify participants. However, all patients
must have been without other therapies for at
least 3 months prior to beginning the study, and
must show active cancer.
people using LifeOne should
be the same.
One half fluid ounce or 15 ml. three times daily. This will last for one year.
2. All people using LifeOne should be instructed
to eliminate sugar and simple carbohydrates from
3. All people using LifeOne should be instructed
to exercise regularly if able.
people using LifeOne
responses will be recorded.
5. All test results will be recorded.
cancer patients who wish to participate in the
research will be treated with the same protocol.
the A.M.A.S. is an actual antibody test, it requires
that the body be able to manufacture antibodies
for accurate results. I have found that lymphocyte
subset panels, that show the patient within the
reference range, produce a consistent and accurate
However, patients with lymphocyte subset panels
which range in the lower third of the subset ranges
produce borderline AMAS test results in many cases.
As the immune system improves, as demostrated
by the lymphocyte subset panel, the AMAS reading
becomes a reliable indicator and shows a positive
finding for cancer. This does not mean the cancer
has worsened. It simply means that immune system
has become more able to produce antibodies to
malignan. Within 6-8 weeks after this increase
in the A.M.A.S., the A.M.A.S. test results should
show a steady decline to a normal range. This
will occur as the subset panel shows movement
toward the upper third of the reference range.
most valuable tool in evaluating the efficacy
of treatment is clinical observation. Most patients
will respond within a week, showing decreased
pain, increased energy, and a general feeling
of increased vigor. It is important to take careful
clinical notes on the patient's general feelings
and how they present themselves.
If patients are currently on pain medication,
as the pain decreases, it is important to decrease
the pain medication. All pain medications have
side effects, and may inhibit absorption of needed
phytochemicals. Opiates have been shown to increase
some cancers' growth and metastasis. If opiates
are required for patient comfort, they may be
prescribed . However, decrease as the pain decreases.
breast tumors regularly. Dramatic decreases in
tumor size within a 2-week period are very common.
It is also common to have breast tenderness decrease
or disappear altogether, within a week or two.
It is important to have CT scans for verification
of both presence and regression of breast tumors.
of skin lesions including basal cell and squamous
cell carcinomas are important. They will often
fall off in a period of 10-30 days. Digital photos
of many cases will be helpful. They must be taken
before any therapeutic intervention.
IV's are contraindicated with cancer patients.
I realize this goes against common practice, but
research dictates that if vitamins or minerals
need a medium for dissolution, a saline solution
Do not raise the serum glucose levels artificially.
Digestive enzymes are very helpful in many cases,
especially when digestive problems are present.